Articles |

Lipid Mediator Dysregulation in Primary Pulmonary Hypertension FREE TO VIEW

Brian W. Christman
Author and Funding Information

From the Center for Lung Research, Vanderbilt University, Nashville, Tenn.

Brian W. Christman, MD, FCCP, Center For Lung Research, T-1217 MCN, Vanderbilt University, Nashville TN 37232-2650

1998 by the American College of Chest Physicians

Chest. 1998;114(3_Supplement):205S-207S. doi:10.1378/chest.114.3_Supplement.205S
Text Size: A A A
Published online


The characteristic arteriopathy of primary pulmonary hypertension (PPH) with attendant endothelial dysfunction provides an opportunity for enhanced cellular activation in the lung. Data from many laboratories support the concept of altered eicosanoid metabolism in PPH. Rigorously quantitative measurements of the excretion of metabolites of thromboxane A2 and prostacyclin support persistent platelet activation and inadequate endothelial response in patients with PPH. Recent studies measuring excretion of prostaglandin D2 metabolites suggest that additional cell sources, such as activated tissue macrophages, may also play a role in the observed elevation in thromboxane excretion and possibly in the pathogenesis of the vascular remodeling. Additional research examining in vivo cell activation in patients receiving therapy with long-term infusion of prostacyclin may further our understanding of the pathogenesis of PPH.




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543